Kidney Cancer Clinical Trial
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
Summary
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.
Eligibility Criteria
Inclusion Criteria:
Diagnosis of metastatic renal cell carcinoma with confirmed CD70 expression
Previously treated with at least 1 tyrosine kinase inhibitor (TKI)
Measurable disease
Eastern Cooperative Oncology Group performance status 0 or 1
Adequate lung and renal function
Exclusion Criteria:
Prior treatment with anti-CD70-directed therapy
Received more than one prior treatment with an mTOR inhibitor
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 8 Locations for this study
Stanford California, 94305, United States
Denver Colorado, 80218, United States
Detroit Michigan, 48201, United States
New York New York, 10065, United States
Chapel Hill North Carolina, 27599, United States
Providence Rhode Island, 02906, United States
Nashville Tennessee, 37203, United States
Seattle Washington, 98109, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.